Drug
Fwy003
Fwy003: highest development phase Phase 2, developed by Novartis. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Novartis
Trials
| Drug | Phase | Indication |
|---|---|---|
| FWY003 NCT07441642 | Phase 2 | Geographic Atrophy Secondary to Age-related Macular Degeneration |
Latest
No recent events.
Follow Fwy003 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.